UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma

Journal of pharmaceutical and biomedical analysis, 2018-02, Vol.149, p.475-481

2018

Volltextzugriff (PDF)

Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry

Journal of pharmaceutical and biomedical analysis, 2011-12, Vol.56 (5), p.1016-1023

2011

Volltextzugriff (PDF)

Modulation of Irinotecan Metabolism by Ketoconazole

Journal of clinical oncology, 2002-07, Vol.20 (14), p.3122-3129

2002

Volltextzugriff (PDF)

Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial

Clinical pharmacology and therapeutics, 2022-02, Vol.111 (2), p.455-460

2022

Volltextzugriff (PDF)

Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of Irinotecan in Cancer Patients

Clinical pharmacology and therapeutics, 2021-05, Vol.109 (5), p.1304-1313

2021

Volltextzugriff (PDF)

Influence of darolutamide on cabazitaxel systemic exposure

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5038-5038

2022

Volltextzugriff (PDF)

Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS

Journal of pharmaceutical and biomedical analysis, 2023-02, Vol.225, p.115233, Article 115233

2023

Volltextzugriff (PDF)

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study

Clinical pharmacology and therapeutics, 2019-06, Vol.105 (6), p.1456-1461

2019

Volltextzugriff (PDF)

Quantification and clinical validation of the selective MET kinase inhibitor DO-2 and its metabolites DO-5 and M3 in human plasma

Journal of pharmaceutical and biomedical analysis, 2024-03, Vol.240, p.115962, Article 115962

2024

Volltextzugriff (PDF)

Fasting protects against the side effects of irinotecan treatment but does not affect anti‐tumour activity in mice

British journal of pharmacology, 2016-03, Vol.173 (5), p.804-814

2016

Volltextzugriff (PDF)

To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry

Journal of pharmaceutical and biomedical analysis, 2021-01, Vol.193, p.113733-113733, Article 113733

2021

Volltextzugriff (PDF)

Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin

Journal of clinical oncology, 2000-01, Vol.18 (1), p.195-203

2000

Volltextzugriff (PDF)

Quantification of ribociclib in dried blood spots by LC–MS/MS: Method development and clinical validation

Journal of pharmaceutical and biomedical analysis, 2021-07, Vol.201, p.114118-114118, Article 114118

2021

Volltextzugriff (PDF)

Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application

Journal of pharmaceutical and biomedical analysis, 2019-08, Vol.172, p.175-182

2019

Volltextzugriff (PDF)

Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

Anti-cancer drugs, 2001-06, Vol.12 (5), p.419-432

2001

Volltextzugriff (PDF)

Development and validation of an UPLC–MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair

Journal of pharmaceutical and biomedical analysis, 2015-10, Vol.114, p.416-425

2015

Volltextzugriff (PDF)

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

Journal of pharmaceutical and biomedical analysis, 2010-03, Vol.51 (4), p.934-941

2010

Volltextzugriff (PDF)

Fentanyl exposure after subcutaneous and transdermal administration: Results from a population pharmacokinetic study in cancer patients

Journal of clinical oncology, 2014, Vol.32 (15_suppl), p.9540-9540

2014

Volltextzugriff (PDF)

Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding

Journal of pharmaceutical and biomedical analysis, 2012-02, Vol.59, p.117-122

2012

Volltextzugriff (PDF)

Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma

Journal of pharmaceutical and biomedical analysis, 2017-11, Vol.149, p.475

2017

Volltextzugriff (PDF)

Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry

Journal of pharmaceutical and biomedical analysis, 2009-12, Vol.50 (5), p.977-982

2009

Volltextzugriff (PDF)

Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

Journal of pharmaceutical and biomedical analysis, 2011-01, Vol.54 (2), p.387-394

2011

Volltextzugriff (PDF)

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein

Anti-cancer drugs, 1999-09, Vol.10 (8), p.719-728

1999

Volltextzugriff (PDF)

Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography

Anti-cancer drugs, 2000-06, Vol.11 (5), p.315-324

2000

Volltextzugriff (PDF)

Growth of Nitrosomonas europaea on hydroxylamine

FEMS microbiology letters, 1995-01, Vol.125 (2), p.179-184

1995

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

KollektionOvid SocietyJournals and Single Titles

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(98)
Tagungsberichte
(1)

Sprache

Englisch
(99)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma

Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry

Modulation of Irinotecan Metabolism by Ketoconazole

Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial

Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of Irinotecan in Cancer Patients

Influence of darolutamide on cabazitaxel systemic exposure

Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study

Quantification and clinical validation of the selective MET kinase inhibitor DO-2 and its metabolites DO-5 and M3 in human plasma

Fasting protects against the side effects of irinotecan treatment but does not affect anti‐tumour activity in mice

To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry

Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin

Quantification of ribociclib in dried blood spots by LC–MS/MS: Method development and clinical validation

Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application

Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

Development and validation of an UPLC–MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

Fentanyl exposure after subcutaneous and transdermal administration: Results from a population pharmacokinetic study in cancer patients

Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding

Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma

Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry

Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein

Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography

Growth of Nitrosomonas europaea on hydroxylamine

Aktive Filter

Suchergebnisse filtern